PH25990A - Site selective genomic modification of yeast of the genus pichia - Google Patents

Site selective genomic modification of yeast of the genus pichia Download PDF

Info

Publication number: PH25990A
Authority: PH; Philippines
Prior art keywords: gene; dna; dna fragment; insertable; fragments
Prior art date: 1985-10-25

Application number

PH34343A

Other languages

English (en)

Inventor

James Michael Cregg

Original Assignee

Philipps Petroleum Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-10-25

Filing date

1986-10-09

Publication date

1992-01-13

1986-10-09 Application filed by Philipps Petroleum Company filed Critical Philipps Petroleum Company

1992-01-13 Publication of PH25990A publication Critical patent/PH25990A/en

Links

238000010362 genome editing Methods 0.000 title claims abstract description 17
241000235648 Pichia Species 0.000 title abstract description 58
240000004808 Saccharomyces cerevisiae Species 0.000 title abstract description 29
108020004414 DNA Proteins 0.000 claims abstract description 137
239000012634 fragment Substances 0.000 claims abstract description 127
108090000623 proteins and genes Proteins 0.000 claims abstract description 109
108010025188 Alcohol oxidase Proteins 0.000 claims abstract description 41
239000003550 marker Substances 0.000 claims abstract description 31
238000000034 method Methods 0.000 claims abstract description 27
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 19
239000013612 plasmid Substances 0.000 claims description 60
241000235058 Komagataella pastoris Species 0.000 claims description 26
230000001131 transforming effect Effects 0.000 claims description 16
230000001580 bacterial effect Effects 0.000 claims description 12
230000008569 process Effects 0.000 claims description 12
239000002773 nucleotide Substances 0.000 claims description 10
125000003729 nucleotide group Chemical group 0.000 claims description 10
230000001105 regulatory effect Effects 0.000 claims description 9
101150061183 AOX1 gene Proteins 0.000 claims description 8
101150006240 AOX2 gene Proteins 0.000 claims description 6
ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 claims description 2
ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 claims description 2
108010085336 phosphoribosyl-AMP cyclohydrolase Proteins 0.000 claims 3
108010020056 Hydrogenase Proteins 0.000 claims 1
230000014509 gene expression Effects 0.000 abstract description 19
238000004519 manufacturing process Methods 0.000 abstract description 14
150000003138 primary alcohols Chemical class 0.000 abstract description 8
230000006798 recombination Effects 0.000 abstract description 2
238000005215 recombination Methods 0.000 abstract description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
210000004027 cell Anatomy 0.000 description 42
229920001817 Agar Polymers 0.000 description 38
239000008272 agar Substances 0.000 description 38
239000002609 medium Substances 0.000 description 21
239000013598 vector Substances 0.000 description 20
230000012010 growth Effects 0.000 description 18
230000009466 transformation Effects 0.000 description 18
230000008929 regeneration Effects 0.000 description 17
238000011069 regeneration method Methods 0.000 description 17
241000588724 Escherichia coli Species 0.000 description 15
235000014304 histidine Nutrition 0.000 description 15
238000003780 insertion Methods 0.000 description 15
230000037431 insertion Effects 0.000 description 15
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 14
229960002885 histidine Drugs 0.000 description 14
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 14
239000000047 product Substances 0.000 description 14
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
102000004196 processed proteins & peptides Human genes 0.000 description 13
108090000765 processed proteins & peptides Proteins 0.000 description 13
230000000694 effects Effects 0.000 description 12
239000000600 sorbitol Substances 0.000 description 12
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 11
239000000243 solution Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
238000012217 deletion Methods 0.000 description 9
230000037430 deletion Effects 0.000 description 9
108010067193 Formaldehyde transketolase Proteins 0.000 description 8
239000008103 glucose Substances 0.000 description 8
229920001184 polypeptide Polymers 0.000 description 8
239000000872 buffer Substances 0.000 description 7
230000002950 deficient Effects 0.000 description 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
229910052799 carbon Inorganic materials 0.000 description 6
238000010276 construction Methods 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
241000364057 Peoria Species 0.000 description 5
241000235070 Saccharomyces Species 0.000 description 5
238000002105 Southern blotting Methods 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
239000008121 dextrose Substances 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
239000000284 extract Substances 0.000 description 5
230000035772 mutation Effects 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
239000000523 sample Substances 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 4
KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
102000002464 Galactosidases Human genes 0.000 description 4
108010093031 Galactosidases Proteins 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
238000000844 transformation Methods 0.000 description 4
239000007222 ypd medium Substances 0.000 description 4
102000053602 DNA Human genes 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108090000854 Oxidoreductases Proteins 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
101150031623 aox gene Proteins 0.000 description 3
229940041514 candida albicans extract Drugs 0.000 description 3
230000029087 digestion Effects 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
235000016709 nutrition Nutrition 0.000 description 3
239000008188 pellet Substances 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
210000005253 yeast cell Anatomy 0.000 description 3
239000012138 yeast extract Substances 0.000 description 3
239000004475 Arginine Substances 0.000 description 2
101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 2
108020004638 Circular DNA Proteins 0.000 description 2
101150069554 HIS4 gene Proteins 0.000 description 2
108090000856 Lyases Proteins 0.000 description 2
239000001888 Peptone Substances 0.000 description 2
108010080698 Peptones Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
244000292604 Salvia columbariae Species 0.000 description 2
235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 2
235000001498 Salvia hispanica Nutrition 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000007984 Tris EDTA buffer Substances 0.000 description 2
YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000003321 amplification Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
235000014167 chia Nutrition 0.000 description 2
230000035611 feeding Effects 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
-1 for example Proteins 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000010354 integration Effects 0.000 description 2
101150066555 lacZ gene Proteins 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
235000019319 peptone Nutrition 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
238000007747 plating Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
241000894007 species Species 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000012546 transfer Methods 0.000 description 2
239000012808 vapor phase Substances 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
101150033839 4 gene Proteins 0.000 description 1
101150041132 AO gene Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
244000040944 Carpobrotus aequilaterus Species 0.000 description 1
235000005809 Carpobrotus aequilaterus Nutrition 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
101150105088 Dele1 gene Proteins 0.000 description 1
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
102000004317 Lyases Human genes 0.000 description 1
241001508691 Martes zibellina Species 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
208000003629 Rupture Diseases 0.000 description 1
JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
101100323865 Xenopus laevis arg1 gene Proteins 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000012143 dye reagent concentrate Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000001279 glycosylating effect Effects 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
150000002411 histidines Chemical class 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000006166 lysate Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000006501 nitrophenyl group Chemical group 0.000 description 1
235000014571 nuts Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
230000010627 oxidative phosphorylation Effects 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000011218 seed culture Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000036259 susceptibility to 4 autoimmune disease Diseases 0.000 description 1
KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
235000019157 thiamine Nutrition 0.000 description 1
229960003495 thiamine Drugs 0.000 description 1
239000011721 thiamine Substances 0.000 description 1
238000003260 vortexing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Saccharide Compounds (AREA)
Peptides Or Proteins (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Investigating Or Analysing Materials By Optical Means (AREA)
Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

PH34343A 1985-10-25 1986-10-09 Site selective genomic modification of yeast of the genus pichia PH25990A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/791,013 US4882279A (en)	1985-10-25	1985-10-25	Site selective genomic modification of yeast of the genus pichia

Publications (1)

Publication Number	Publication Date
PH25990A true PH25990A (en)	1992-01-13

Family

ID=25152397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH34343A PH25990A (en)	1985-10-25	1986-10-09	Site selective genomic modification of yeast of the genus pichia

Country Status (26)

Country	Link
US (1)	US4882279A (pl)
EP (2)	EP0226752B1 (pl)
JP (1)	JP2614215B2 (pl)
KR (1)	KR930002738B1 (pl)
CN (1)	CN86107108A (pl)
AT (2)	ATE98695T1 (pl)
AU (2)	AU581107B2 (pl)
CA (1)	CA1339209C (pl)
DD (1)	DD255544A5 (pl)
DE (2)	DE3689411T2 (pl)
DK (1)	DK510786A (pl)
EG (1)	EG17985A (pl)
ES (2)	ES2061433T3 (pl)
FI (1)	FI98931C (pl)
HU (1)	HU208552B (pl)
IE (1)	IE68454B1 (pl)
IL (1)	IL80286A (pl)
IN (1)	IN166443B (pl)
MX (1)	MX168390B (pl)
NO (1)	NO176923C (pl)
NZ (1)	NZ217809A (pl)
PH (1)	PH25990A (pl)
PL (1)	PL154843B1 (pl)
PT (1)	PT83618B (pl)
YU (1)	YU46758B (pl)
ZA (1)	ZA867650B (pl)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5032516A (en) *	1985-10-25	1991-07-16	Phillips Petroleum Company	Pichia pastoris alcohol oxidase II regulatory region
US4895800A (en) *	1985-11-26	1990-01-23	Phillips Petroleum Company	Yeast production of hepatitis B surface antigen
IL90021A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Process for the production of interferon
IL89989A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human interleukin-2 in methylotrophic yeasts
IL89992A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human serum albumin in methylotrophic yeasts
IL89993A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of the hiv 24kda gag protein in methylotrophic yeasts
IL89991A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of hepatitis b pres2 protein in methylotrophic yeasts
AT390267B (de) *	1988-06-08	1990-04-10	Vogelbusch Gmbh	Verfahren zum markieren und identifizieren von industriell eingesetzten mikroorganismen, vorzugsweise hefestaemmen
US5102789A (en) *	1989-03-15	1992-04-07	The Salk Institute Biotechnology/Industrial Associates, Inc.	Production of epideramal growth factor in pichia pastoris yeast cells
US5204252A (en) *	1989-02-08	1993-04-20	Henkel Research Corporation	Candida tropicalis transformation system
AU5196290A (en) *	1989-02-13	1990-09-05	Salk Institute Biotechnology/Industrial Associates, Inc., The	Production of superoxide dismutase in pichia pastoris yeast cells
CA2017176A1 (en) *	1989-05-22	1990-11-22	Yoshitomi Pharmaceutical Industries Ltd.	Albumin gene-containing plasmid, transformant carrying same, production of such transformant and production of albumin
JPH0669365B2 (ja) *	1989-05-22	1994-09-07	株式会社ミドリ十字	アルブミン遺伝子を含むプラスミド、形質転換体、形質転換体の製造方法、アルブミンの製造方法
US6440681B1 (en)	1990-04-03	2002-08-27	Merck & Co., Inc.	Methods for identifying agonists and antagonists for human neuronal nicotinic acetylcholine receptors
US5369028A (en) *	1990-04-03	1994-11-29	The Salk Institute Biotechnology/Industrial Associates, Inc.	DNA and mRNA encoding human neuronal nicotinic acetylcholine receptor compositions and cells transformed with same
US5258302A (en) *	1990-07-03	1993-11-02	The Salk Institute Biotechnology/Industrial Associates, Inc.	DNA for expression of aprotinin in methylotrophic yeast cells
CA2090969C (en) *	1990-09-04	2001-08-21	Russell Arthur Brierley	Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5612198A (en) *	1990-09-04	1997-03-18	The Salk Institute	Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5268273A (en) *	1990-12-14	1993-12-07	Phillips Petroleum Company	Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising same
WO1992013951A1 (en) *	1991-02-04	1992-08-20	The Salk Institute Biotechnology/Industrial Associates, Inc.	Production of human serum albumin in methylotrophic yeast cells
CA2063890C (en) *	1991-03-27	2007-03-13	Masami Miura	Mutant aox2 promoter, microorganism carrying same, method of preparation thereof and production of heterologous protein using such microorganism
AU661844B2 (en) *	1991-04-01	1995-08-10	Merck Sharp & Dohme Corp.	Genes which influence (pichia) proteolytic activity, and uses therefor
CA2058820C (en) *	1991-04-25	2003-07-15	Kotikanyad Sreekrishna	Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
US5330901A (en) *	1991-04-26	1994-07-19	Research Corporation Technologies, Inc.	Expression of human serum albumin in Pichia pastoris
US5665600A (en) *	1991-09-18	1997-09-09	Research Corporation Technologies, Inc.	Pichia pastoris linear plasmids and DNA fragments thereof
EP0690921B1 (en) *	1993-03-03	1997-05-28	E.I. Du Pont De Nemours And Company	Production of glycolate oxidase in methylotrophic yeast
JP3628691B2 (ja) *	1993-03-08	2005-03-16	メルクエンドカンパニーインコーポレーテッド	ヒト神経細胞性ニコチン性アセチルコリン受容体組成物およびそれらの使用方法
JPH08509607A (ja)	1993-04-20	1996-10-15	ザソールクインスチチュートバイオテクノロジー／インダストリアルアソシエイツ，インコーポレイテッド	ヒトｎ−メチル−ｄ−アスパラギン酸受容体サブユニット、これをコードする核酸およびその用途
JP3937445B2 (ja) *	1993-05-28	2007-06-27	ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン	グリオキシル酸／アミノメチルホスホン酸ジアルキル混合物の製造法
US5521297A (en)	1993-06-04	1996-05-28	Salk Institute Biotechnology/Industrial Associates	Nucleic acids encoding human metabotropic glutamate receptors
US6001581A (en)	1993-06-04	1999-12-14	Sibia Neurosciences, Inc.	Cation-based bioassay using human metabotropic glutamate receptors
US5912122A (en)	1993-06-04	1999-06-15	Sibia Neurosciences, Inc.	Nucleic acids encoding and method for detecting nucleic acid encoding human metabotropic glutamate receptor subtype mGluR6
US6495343B1 (en)	1993-06-18	2002-12-17	The Salk Institute For Biological Studies	Cloning and recombinant production of CRF receptor(s)
US6638905B2 (en)	1993-06-18	2003-10-28	The Salk Institute For Biological Studies	Cloning and recombinant production of CFR receptor(s)
GB2287941B (en) *	1993-11-08	1998-01-28	Salk Inst Biotech Ind	Human alpha2 neuronal nicotinic acetylcholine receptor compositions and methods employing same
DK0733059T3 (da) *	1993-12-09	2000-10-16	Univ Jefferson	Forbindelser og fremgangsmåder til site-rettede mutationer i eukaryote celler
CA2202351A1 (en) *	1994-10-18	1996-04-25	George Phillip Vlasuk	Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5863894A (en) *	1995-06-05	1999-01-26	Corvas International, Inc.	Nematode-extracted anticoagulant protein
US6090916A (en) *	1994-10-18	2000-07-18	Corvas International, Inc.	Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5866543A (en) *	1995-06-05	1999-02-02	Corvas International, Inc.	Nematode-extracted anticoagulant protein
US5945275A (en) *	1994-10-18	1999-08-31	Corvas International, Inc.	Nematode-extracted anticoagulant protein
US5866542A (en) *	1994-10-18	1999-02-02	Corvas International, Inc.	Nematode-extracted anticoagulant protein
US5872098A (en) *	1995-06-05	1999-02-16	Corvas International, Inc.	Nematode-extracted anticoagulant protein
EP2431462A3 (en)	1995-03-17	2012-05-23	Novozymes A/S	Novel endoglucanases
US6485967B1 (en)	1995-06-07	2002-11-26	Merck & Co., Inc.	Human neuronal nicotinic acetylcholine receptor α6 and β3 nucleic acid
AU7719696A (en) *	1995-10-18	1997-05-07	New York Blood Center, Inc., The	Recombinant alpha-n-acetylgalactosaminidase enzyme
US6001597A (en) *	1995-11-09	1999-12-14	Zymogenetics, Inc.	Compositions and methods for producing heterologous polypeptides in Pichia methanolica
WO1997017451A2 (en) *	1995-11-09	1997-05-15	Zymogenetics, Inc.	Production of gad65 in methylotrophic yeast
EP1975177B1 (en)	1996-03-01	2011-04-13	Novo Nordisk A/S	An appetite-suppressing peptide, its compositions and use
US5731181A (en) *	1996-06-17	1998-03-24	Thomas Jefferson University	Chimeric mutational vectors having non-natural nucleotides
UA75316C2 (uk)	1996-10-16	2006-04-17	Займодженетікс, Інк.	Гомологи з фактором росту фібробласта
MX9605082A (es)	1996-10-24	1998-04-30	Univ Autonoma De Nuevo Leon	Levaduras metilotroficas modificadas geneticamente para la produccion y secrecion de hormona de crecimiento humano.
CZ20011026A3 (cs)	1998-09-23	2001-08-15	Zymogenetics, Inc.	Izolovaný polynukleotid, expresní vektor, kultivovaná buňka, konstrukt DNA, způsob produkce proteinu, izolovaný polypeptid, způsob produkce protilátky, protilátka a způsob detekce
DE69939330D1 (de)	1998-12-07	2008-09-25	Zymogenetics Inc	Wachstumsfaktor-homologe zvegf-3
US6780615B1 (en)	1998-12-31	2004-08-24	Genway Biotech Inc.	Production of recombinant monellin using methylotrophic yeast expression system
CZ303272B6 (cs)	1999-01-07	2012-07-11	Zymogenetics, Inc.	Farmaceutický prostredek obsahující fúzní protein, izolovaná molekula polynukleotidu, expresní vektor, kultivovaná bunka, zpusob prípravy polypeptidu a izolovaný polypeptid
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
UA84387C2 (ru)	1999-03-09	2008-10-27	Займодженетикс, Инк.	Человеческий цитокин как лиганд зальфа рецептора и его применение
US7504253B2 (en) *	1999-06-11	2009-03-17	The Burnham Institute For Medical Research	Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
DE60034564T2 (de)	1999-07-07	2007-12-27	Zymogenetics, Inc., Seattle	Menschlicher cytokinrezeptor
EP2194130A1 (en)	1999-12-23	2010-06-09	ZymoGenetics, L.L.C.	Cytokine ZCYTO18
WO2001087933A2 (en)	2000-05-11	2001-11-22	Zymogenetics, Inc.	Zsig33-like peptides
EP1325115B1 (en)	2000-06-26	2016-07-27	ZymoGenetics, Inc.	Cytokine receptor zcytor17
US7598055B2 (en) *	2000-06-28	2009-10-06	Glycofi, Inc.	N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7029872B2 (en) *	2000-06-28	2006-04-18	Glycofi, Inc	Methods for producing modified glycoproteins
US7449308B2 (en)	2000-06-28	2008-11-11	Glycofi, Inc.	Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7625756B2 (en)	2000-06-28	2009-12-01	GycoFi, Inc.	Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US8697394B2 (en) *	2000-06-28	2014-04-15	Glycofi, Inc.	Production of modified glycoproteins having multiple antennary structures
US7863020B2 (en)	2000-06-28	2011-01-04	Glycofi, Inc.	Production of sialylated N-glycans in lower eukaryotes
ES2286128T3 (es)	2000-06-30	2007-12-01	Zymogenetics, Inc.	Proteina zcyto21 tipo interferon.
EP2028275A3 (en)	2000-06-30	2009-05-06	VIB vzw	Protein glycosylation modification in pichia pastoris
US7009045B2 (en) *	2000-07-14	2006-03-07	Archer-Daniels-Midland Company	Transformation systems for flavinogenic yeast
EP1736545A3 (en)	2000-08-08	2007-03-28	ZymoGenetics, Inc.	Soluble zcytor 11 cytokine receptors
AU2002238052A1 (en)	2001-02-20	2002-09-04	Zymogenetics, Inc.	Antibodies that bind both bcma and taci
ES2432967T3 (es)	2001-03-22	2013-12-05	Novo Nordisk Health Care Ag	Derivados del Factor VII de coagulación
WO2002081650A2 (en)	2001-04-05	2002-10-17	The Board Of Regents Of The University Of Nebraska	Alcohol oxidase 1 regulatory nucleotide sequences for heterologous gene expression in yeast
PL403488A1 (pl)	2001-05-24	2013-07-08	Zymogenetics, Inc.	Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
EP2130919A1 (en)	2001-11-05	2009-12-09	ZymoGenetics, Inc.	IL-21 antagonists
WO2003054155A2 (en) *	2001-12-19	2003-07-03	Bristol-Myers Squibb Company	Pichia pastoris formate dehydrogenase and uses therefor
RU2490276C2 (ru)	2002-01-18	2013-08-20	Займоджинетикс, Инк.	Новый лиганд рецептора цитокина zcytor17
WO2004003140A2 (en)	2002-01-18	2004-01-08	Zymogenetics, Inc.	Cytokine receptor zcytor17 multimers
CA2482485A1 (en) *	2002-04-15	2003-10-30	Merck & Co., Inc.	Matrix analysis of gene expression in cells (magec)
CN1659274A (zh)	2002-04-19	2005-08-24	津莫吉尼蒂克斯公司	细胞因子受体
US7252933B2 (en)	2002-06-26	2007-08-07	Flanders Interuniversity Institute For Biotechnology	Protein glycosylation modification in methylotrophic yeast
US7118901B2 (en) *	2002-12-18	2006-10-10	Roche Diagnostics Operations, Inc.	Recombinant bovine pancreatic desoxyribonuclease I with high specific activity
ATE387494T1 (de) *	2002-12-20	2008-03-15	Hoffmann La Roche	Hitzelabile desoxyribonuklease i-varianten
US7332299B2 (en)	2003-02-20	2008-02-19	Glycofi, Inc.	Endomannosidases in the modification of glycoproteins in eukaryotes
EP1460425A1 (en) *	2003-03-17	2004-09-22	Boehringer Mannheim Gmbh	Deglycosylated enzymes for conjugates
JP4808157B2 (ja)	2003-08-07	2011-11-02	ザイモジェネティクスリミテッドライアビリティカンパニー	Ｉｌ−２８およびｉｌ−２９の均一な調製物
CN101870729A (zh)	2003-09-09	2010-10-27	诺和诺德医疗保健公司	凝固因子ⅶ多肽
ES2337684T3 (es) *	2003-12-05	2010-04-28	F. Hoffmann-La Roche Ag	Carboxipeptidasa b recombinante y su purificacion.
EP2325318A1 (en)	2004-02-13	2011-05-25	Novozymes A/S	Protease variants
CA2558811A1 (en)	2004-03-08	2005-09-22	Zymogenetics, Inc.	Dimeric fusion proteins and materials and methods for producing them
US7351689B2 (en)	2004-07-29	2008-04-01	Zymogenetics, Inc.	Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
EP1781784A2 (en)	2004-08-02	2007-05-09	BASF Plant Science GmbH	Method for isolation of transcription termination sequences
WO2006086396A2 (en)	2005-02-08	2006-08-17	Zymogenetics, Inc.	Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
AU2006237329B2 (en)	2005-04-18	2012-04-12	Novo Nordisk A/S	IL-21 variants
EP3683230A1 (en)	2005-05-12	2020-07-22	ZymoGenetics, Inc.	Compositions and methods for modulating immune responses
WO2006130657A2 (en) *	2005-05-31	2006-12-07	Bristol-Myers Squibb Company	Stereoselective reduction process for the preparation of pyrrolotriazine compounds
US8808696B2 (en)	2005-08-09	2014-08-19	Ares Trading S.A.	Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
KR20080056714A (ko) *	2005-08-09	2008-06-23	지모제넥틱스, 인코포레이티드	ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법
ATE513921T1 (de)	2005-08-16	2011-07-15	Novo Nordisk As	Verfahren zur herstellung reifer insulinpolypeptide
JP5690047B2 (ja)	2005-09-14	2015-03-25	ノボノルディスクヘルスケアアーゲー	ヒト凝固第ｖｉｉ因子ポリペプチド
ATE517919T1 (de) *	2005-09-14	2011-08-15	Sanofi Aventis Deutschland	Spaltung von insulinvorstufen durch eine trypsinvariante
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
BRPI0616589A2 (pt)	2005-09-28	2011-06-28	Zymogenetics Inc	polipeptìdeo, e, métodos para produzir um anticorpo para um polipeptìdeo, para reduzir ou inibir a inflamação e para tratar um mamìfero afligido com uma doença inflamatória
WO2007134326A2 (en) *	2006-05-15	2007-11-22	Ares Trading S.A.	Methods for treating autoimmune diseases using a taci-ig fusion molecule
WO2008037735A1 (en)	2006-09-27	2008-04-03	Novo Nordisk A/S	Method for making maturated insulin polypeptides
JP5967861B2 (ja)	2007-04-03	2016-08-10	オキシレインユーケーリミテッド	分子のグリコシル化
WO2008157263A2 (en)	2007-06-15	2008-12-24	Arkansas State University	Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
CN101918437B (zh)	2007-11-21	2013-08-14	罗斯基勒大学	具有冰结合活性的多肽
US20110027337A1 (en) *	2007-12-21	2011-02-03	Ifxa A/S	Protease inhibitor
KR101720760B1 (ko) *	2008-01-25	2017-03-28	오르후스 우니베르시테트	Ｉｇｆｂｐ-4에 대한 ｐａｐｐ-ａ 활성의 선택적 엑소사이트 억제
BRPI0910286A2 (pt) *	2008-03-03	2015-09-29	Abbott Lab	métodos para transformação de levedura
JP5425180B2 (ja)	2008-03-27	2014-02-26	ザイモジェネティクス，インコーポレイテッド	ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
US20110081698A1 (en) *	2008-05-14	2011-04-07	Bio-Energay Corporation	Method and introduction of gene into yeast cell, and vector for the method
WO2009158696A1 (en)	2008-06-27	2009-12-30	Zymogenetics, Inc.	SOLUBLE HYBRID Fcγ RECEPTORS AND RELATED METHODS
CN102245771B (zh)	2008-12-16	2013-04-10	诺瓦提斯公司	酵母展示系统
DK3178835T3 (da)	2009-02-03	2019-06-24	Amunix Pharmaceuticals Inc	Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US20120107267A1 (en)	2009-03-11	2012-05-03	Novo Nordisk A/S	Interleukin-21 variants having antagonistic binding to the il-21 receptor
CA2767755C (en)	2009-07-17	2021-10-12	Rigshospitalet	Inhibitors of complement activation
CA2771999A1 (en)	2009-08-24	2011-03-10	Amunix Operating Inc.	Coagulation factor vii compositions and methods of making and using same
KR102000383B1 (ko)	2009-09-29	2019-07-15	유니버시테이트 젠트	만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
US20130053550A1 (en)	2009-11-19	2013-02-28	Oxyrane Uk Limited	Yeast strains producing mammalian-like complex n-glycans
EP2504355B1 (en)	2009-11-25	2015-07-22	Novo Nordisk A/S	Method for making polypeptides
ES2583259T3 (es)	2009-12-01	2016-09-20	Novo Nordisk A/S	Nuevas liasas alfa-amidantes de peptidil alfa-hidroxiglicina
AU2011222883B2 (en)	2010-03-05	2016-05-26	Omeros Corporation	Chimeric inhibitor molecules of complement activation
EP2580238A1 (en)	2010-06-09	2013-04-17	Zymogenetics, Inc.	Dimeric vstm3 fusion proteins and related compositions and methods
JP6131190B2 (ja)	2010-09-29	2017-05-17	オキシレインユーケーリミテッド	リン酸化ｎ−グリカンの脱マンノシル化
BR112013007616B1 (pt)	2010-09-29	2023-01-24	Oxyrane Uk Limited	Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero
JP2015503338A (ja)	2011-12-30	2015-02-02	オキシレインユーケーリミテッド	組換えタンパク質の分解を低減させる方法および材料
CA2862149C (en)	2012-02-01	2022-07-26	Synthetic Genomics, Inc.	Materials and methods for the synthesis of error-minimized nucleic acid molecules
PL2812024T3 (pl)	2012-02-09	2018-09-28	Var2 Pharmaceuticals Aps	Celowanie glikanów siarczanu chondroityny
CN111548418A (zh)	2012-02-15	2020-08-18	比奥贝拉蒂治疗公司	因子viii组合物及其制备和使用方法
WO2013123457A1 (en)	2012-02-15	2013-08-22	Biogen Idec Ma Inc.	Recombinant factor viii proteins
CA2867237C (en)	2012-03-15	2024-01-02	Wouter Vervecken	Methods and materials for treatment of pompe's disease
KR101958234B1 (ko) *	2012-05-09	2019-03-14	엘지이노텍 주식회사	보이스 코일 모터
CN104704118A (zh)	2012-10-15	2015-06-10	诺和诺德保健Ag（股份有限公司）	凝血因子vii多肽
US20190040368A1 (en)	2013-03-05	2019-02-07	Oxyrane Uk Limited	Production of catalytically active type i sulfatase
TWI657094B (zh)	2013-03-21	2019-04-21	全民科學與工業研究機構	三螺旋蛋白質之純化
US20160115216A1 (en)	2013-06-07	2016-04-28	Novo Nordisk A/S	Method for Making Mature Insulin Polypeptides
WO2014202089A2 (en)	2013-06-18	2014-12-24	Roskilde Universitet	Variants of anti-freeze polypeptides
US10548953B2 (en)	2013-08-14	2020-02-04	Bioverativ Therapeutics Inc.	Factor VIII-XTEN fusions and uses thereof
TWI738631B (zh)	2013-09-09	2021-09-11	德商贏創運營有限公司	經修飾之細菌類膠原蛋白蛋白質
EA201691111A1 (ru)	2014-01-10	2017-01-30	Байоджен Ма Инк.	Химерные белки фактора viii и их применение
US20170211063A1 (en)	2014-07-30	2017-07-27	Daiichi Sankyo Company, Limited	Method for improved high-level secretory production of protein
UA126016C2 (uk)	2015-08-03	2022-08-03	Біовератів Терапеутікс Інк.	Злитий білок фактора іх
CN107969127B (zh)	2015-09-08	2022-09-06	赛瑞品股份有限公司	Apoa-1融合多肽及相关组合物和方法
HK1251480A1 (zh)	2015-09-21	2019-02-01	Aptevo Research And Development Llc	Cd3结合多肽
KR20190090827A (ko)	2016-12-02	2019-08-02	바이오버라티브 테라퓨틱스 인크.	키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
WO2018136163A2 (en)	2016-12-09	2018-07-26	Theripion, Inc.	Tandem apoa-1 fusion polypeptides
CN110088279A (zh) *	2016-12-15	2019-08-02	株式会社钟化	新型宿主细胞及使用了其的目标蛋白质的制造方法
US11725060B2 (en)	2017-07-20	2023-08-15	Aptevo Reserch and Development LLC	Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
SG11202005692WA (en)	2017-12-20	2020-07-29	Harbour Biomed Shanghai Co Ltd	Antibodies binding ctla-4 and uses thereof
WO2019132765A1 (en)	2017-12-27	2019-07-04	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
US10150801B1 (en)	2017-12-27	2018-12-11	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
WO2019173541A1 (en) *	2018-03-06	2019-09-12	Miraculex, Inc.	Recombinantly expressed taste modifying polypeptides and preparations and formulations comprising the same
KR102914074B1 (ko)	2018-05-18	2026-01-16	바이오버라티브 테라퓨틱스 인크.	A형 혈우병의 치료 방법
CN112789504A (zh)	2018-07-13	2021-05-11	瓦克特诊断有限责任公司	使用重组疟疾蛋白var2csa分离胎儿来源的循环细胞
CN111378585B (zh)	2018-12-28	2023-06-16	丰益(上海)生物技术研发中心有限公司	用于表达外源基因的毕赤酵母突变株
US12270034B2 (en) *	2019-04-01	2025-04-08	Universität Für Bodenkultur Wien	Mut- methylotrophic yeast
WO2021040610A1 (en)	2019-08-26	2021-03-04	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
US10675332B1 (en)	2019-08-26	2020-06-09	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
US20240293504A1 (en)	2020-06-22	2024-09-05	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and combinations for use in the treatment of cancer
EP4294916A2 (en)	2021-02-19	2023-12-27	Theripion, Inc.	Dnase fusion polypeptides and related compositions and methods
CN120584137A (zh)	2023-01-06	2025-09-02	阿帕特夫研究和发展有限公司	双特异性pd-l1和cd40结合分子以及其用途
WO2024259220A1 (en)	2023-06-15	2024-12-19	Theripion, Inc.	Pon3 and evolved pon1 fusion polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4530901A (en) *	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4414329A (en) *	1980-01-15	1983-11-08	Phillips Petroleum Company	Biochemical conversions by yeast fermentation at high cell densities
JPS57206699A (en) *	1981-06-10	1982-12-18	Takeda Chem Ind Ltd	Plasmid patm 3 and its preparation
US4837148A (en) *	1984-10-30	1989-06-06	Phillips Petroleum Company	Autonomous replication sequences for yeast strains of the genus pichia
US4855231A (en) *	1984-10-30	1989-08-08	Phillips Petroleum Company	Regulatory region for heterologous gene expression in yeast
US4879231A (en) *	1984-10-30	1989-11-07	Phillips Petroleum Company	Transformation of yeasts of the genus pichia

1985
- 1985-10-25 US US06/791,013 patent/US4882279A/en not_active Expired - Lifetime
1986
- 1986-07-29 CA CA000514838A patent/CA1339209C/en not_active Expired - Lifetime
- 1986-10-06 IE IE263786A patent/IE68454B1/en not_active IP Right Cessation
- 1986-10-06 NZ NZ217809A patent/NZ217809A/en unknown
- 1986-10-07 ZA ZA867650A patent/ZA867650B/xx unknown
- 1986-10-08 MX MX003971A patent/MX168390B/es unknown
- 1986-10-08 IN IN731/CAL/86A patent/IN166443B/en unknown
- 1986-10-09 PH PH34343A patent/PH25990A/en unknown
- 1986-10-10 IL IL80286A patent/IL80286A/xx not_active IP Right Cessation
- 1986-10-14 AU AU63882/86A patent/AU581107B2/en not_active Expired
- 1986-10-20 JP JP61249403A patent/JP2614215B2/ja not_active Expired - Lifetime
- 1986-10-20 KR KR1019860008825A patent/KR930002738B1/ko not_active Expired - Fee Related
- 1986-10-22 EG EG659/86A patent/EG17985A/xx active
- 1986-10-23 AT AT86114700T patent/ATE98695T1/de not_active IP Right Cessation
- 1986-10-23 AT AT93105818T patent/ATE197962T1/de not_active IP Right Cessation
- 1986-10-23 DE DE3689411T patent/DE3689411T2/de not_active Expired - Lifetime
- 1986-10-23 ES ES86114700T patent/ES2061433T3/es not_active Expired - Lifetime
- 1986-10-23 EP EP86114700A patent/EP0226752B1/en not_active Expired - Lifetime
- 1986-10-23 DE DE3650749T patent/DE3650749T2/de not_active Expired - Lifetime
- 1986-10-23 ES ES93105818T patent/ES2152233T3/es not_active Expired - Lifetime
- 1986-10-23 YU YU180386A patent/YU46758B/sh unknown
- 1986-10-23 EP EP93105818A patent/EP0560401B1/en not_active Expired - Lifetime
- 1986-10-24 PL PL1986262030A patent/PL154843B1/pl unknown
- 1986-10-24 HU HU864480A patent/HU208552B/hu not_active IP Right Cessation
- 1986-10-24 PT PT83618A patent/PT83618B/pt not_active IP Right Cessation
- 1986-10-24 DK DK510786A patent/DK510786A/da not_active Application Discontinuation
- 1986-10-24 FI FI864319A patent/FI98931C/fi not_active IP Right Cessation
- 1986-10-24 NO NO864275A patent/NO176923C/no unknown
- 1986-10-24 CN CN198686107108A patent/CN86107108A/zh active Pending
- 1986-10-24 DD DD29558586A patent/DD255544A5/de unknown
1988
- 1988-04-15 AU AU14699/88A patent/AU593436B2/en not_active Expired

Also Published As

Publication number	Publication date
EP0226752B1 (en)	1993-12-15
AU581107B2 (en)	1989-02-09
AU1469988A (en)	1988-07-21
KR930002738B1 (ko)	1993-04-09
NO176923C (no)	1995-06-21
PT83618B (pt)	1988-10-14
NZ217809A (en)	1991-07-26
FI864319A0 (fi)	1986-10-24
AU593436B2 (en)	1990-02-08
US4882279A (en)	1989-11-21
YU180386A (sh)	1992-12-21
FI98931C (fi)	1997-09-10
CA1339209C (en)	1997-08-05
ATE197962T1 (de)	2000-12-15
DE3650749T2 (de)	2001-04-05
IE940325L (en)	1987-04-25
NO864275L (no)	1987-04-27
CN86107108A (zh)	1987-06-03
IN166443B (pl)	1990-05-12
PT83618A (en)	1986-11-01
FI98931B (fi)	1997-05-30
PL262030A1 (en)	1987-09-07
DE3650749D1 (de)	2001-01-11
EP0226752A1 (en)	1987-07-01
IL80286A (en)	1991-12-12
ZA867650B (en)	1987-05-27
AU6388286A (en)	1987-04-30
JP2614215B2 (ja)	1997-05-28
ATE98695T1 (de)	1994-01-15
DD255544A5 (de)	1988-04-06
DK510786A (da)	1987-04-26
ES2152233T3 (es)	2001-02-01
PL154843B1 (en)	1991-09-30
YU46758B (sh)	1994-05-10
DE3689411T2 (de)	1994-07-21
IE862637L (en)	1987-04-25
HUT44612A (en)	1988-03-28
FI864319L (fi)	1987-04-26
IE68454B1 (en)	1996-06-26
JPS62104585A (ja)	1987-05-15
NO176923B (no)	1995-03-13
DK510786D0 (da)	1986-10-24
HU208552B (en)	1993-11-29
EP0560401B1 (en)	2000-12-06
MX168390B (es)	1993-05-21
ES2061433T3 (es)	1994-12-16
KR870004141A (ko)	1987-05-07
EG17985A (en)	1991-11-30
DE3689411D1 (de)	1994-01-27
IL80286A0 (en)	1987-01-30
NO864275D0 (no)	1986-10-24
EP0560401A1 (en)	1993-09-15

Publication	Publication Date	Title
CA1339209C (en)	1997-08-05	Site selective genomic modification of yeast of the genus pichia
US5166329A (en)	1992-11-24	DNA encoding the alcohol oxidase 2 gene of yeast of the genus Pichia
US4885242A (en)	1989-12-05	Genes from pichia histidine pathway and uses thereof
FI95285C (fi)	1996-01-10	2 m-plasmidivektori, menetelmä sen valmistamiseksi sekä sen käyttö
AU601768B2 (en)	1990-09-20	Yeast production of human tumor necrosis factor
FI81379B (fi)	1990-06-29	Anvaendning av kluyveromyces-jaest saosom vaerd foer transformering och uttryckning av fraemmande gener.
EP0460716B2 (en)	1999-12-15	Yeast expression systems with vectors having GAPDH promoters, and synthesis of HBsAg
US4895800A (en)	1990-01-23	Yeast production of hepatitis B surface antigen
US5135868A (en)	1992-08-04	Cultures of yeast of the genus Pichia altered by site selective genomic modification
IE852472L (en)	1986-04-30	Autonomous yeast replication sequences
FI104264B (fi)	1999-12-15	Menetelmä sekundääristen metaboliittien tuoton parantamiseksi käyttämällä rykelmöityjä biosynteettisiä geenejä
EP0225078A2 (en)	1987-06-10	Composite expression cassettes for fungal transformation
US5616474A (en)	1997-04-01	K. lactis transaldolase gene promoter and use thereof
US7973215B2 (en)	2011-07-05	Method for the introduction of a heterologous polynucleotide into a mushroom
JPH0576375A (ja)	1993-03-30	改良された酵母ベクター
EP0549062B1 (en)	1999-03-17	A eukaryotic expression system
WO1995009914A1 (en)	1995-04-13	Multicloning vector, expression vector, and production of foreign protein with expression vector
EP0248227A1 (en)	1987-12-09	Yeast production of streptokinase
IE83234B1 (en)	2004-01-14	DNA fragment encoding an AOX
US20050289666A1 (en)	2005-12-29	Starch-inducible promoters, recombinant gene constructs, and methods of regulating gene expression
JPH03262487A (ja)	1991-11-22	ヒト血清アルブミンの安定な製造方法